Daré Bioscience (DARE) Set to Announce Quarterly Earnings on Thursday

Daré Bioscience (NASDAQ:DARE) will be issuing its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter.

Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 EPS for the quarter, topping the consensus estimate of ($0.57) by $2.09. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million. On average, analysts expect Daré Bioscience to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Daré Bioscience Trading Up 2.8 %

Shares of NASDAQ DARE opened at $4.03 on Friday. Daré Bioscience has a 12 month low of $3.05 and a 12 month high of $7.56. The firm has a market capitalization of $34.46 million, a price-to-earnings ratio of -3.59 and a beta of 1.34. The business has a 50-day moving average of $3.51 and a 200-day moving average of $3.91.

Analyst Ratings Changes

Several analysts have weighed in on the company. Maxim Group reiterated a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a research note on Thursday, October 24th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.